May 2, 2013

CanSinotech submitted Clinical Trial Application (CTA) of “AC Meningococcal Conjugate Vaccine” to China Food and Drug Administration.

Compare to Meningococcal polysaccharide Vccine, this present invention describes a combined vaccine that offers better protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of two distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.